These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 28393570)

  • 1. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
    Gundapaneni BK; Sultan MB; Keohane DJ; Schwartz JH
    Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Amass L; Li H; Gundapaneni BK; Schwartz JH; Keohane DJ
    Orphanet J Rare Dis; 2018 Dec; 13(1):225. PubMed ID: 30558645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
    Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment for familial amyloid polyneuropathy.
    Magrinelli F; Fabrizi GM; Santoro L; Manganelli F; Zanette G; Cavallaro T; Tamburin S
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012395. PubMed ID: 32311072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
    J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
    Lozeron P; Théaudin M; Mincheva Z; Ducot B; Lacroix C; Adams D;
    Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafamidis: a review of its use in familial amyloid polyneuropathy.
    Scott LJ
    Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.
    Barroso FA; Judge DP; Ebede B; Li H; Stewart M; Amass L; Sultan MB
    Amyloid; 2017 Sep; 24(3):194-204. PubMed ID: 28758793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
    Conceição I; Miranda B; Castro J; de Carvalho M
    Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
    Sanso MAR; Rodriguez AR; Vicente LM; Sevilla T; Garro CB; Martín JF; Vicente AA; de la Prida MM; Dávila LG; Vázquez LG; Valle FM; Pons CC; Bau AF; Barroso EC; López IL; González-Moreno J
    Med Clin (Barc); 2024 May; 162(9):e27-e32. PubMed ID: 38556397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical measures in transthyretin familial amyloid polyneuropathy.
    Coelho T; Vinik A; Vinik EJ; Tripp T; Packman J; Grogan DR
    Muscle Nerve; 2017 Mar; 55(3):323-332. PubMed ID: 27422379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
    J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.